Sarepta Therapeutics (SRPT) Competitors

$19.14 -0.27 (-1.37%)

As of 02:58 PM Eastern

SRPT vs. CTMX, EDIT, PRAX, PCVX, and CYTK

Should you buy Sarepta Therapeutics stock or one of its competitors? MarketBeat compares Sarepta Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sarepta Therapeutics include CytomX Therapeutics (CTMX), Editas Medicine (EDIT), Praxis Precision Medicines (PRAX), Vaxcyte (PCVX), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry.

How does Sarepta Therapeutics compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 6.6% of CytomX Therapeutics shares are held by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Sarepta Therapeutics has a net margin of -2.94% compared to CytomX Therapeutics' net margin of -166.40%. Sarepta Therapeutics' return on equity of 7.56% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-54.37%	-36.59%
Sarepta Therapeutics	-2.94%	7.56%	2.94%

CytomX Therapeutics presently has a consensus target price of $12.78, indicating a potential upside of 232.32%. Sarepta Therapeutics has a consensus target price of $27.71, indicating a potential upside of 44.80%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe CytomX Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Sarepta Therapeutics	6 Sell rating(s)	13 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.11

CytomX Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

CytomX Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	8.59	-$17.37M	-$0.41	N/A
Sarepta Therapeutics	$2.20B	0.92	-$713.41M	-$0.96	N/A

In the previous week, Sarepta Therapeutics had 9 more articles in the media than CytomX Therapeutics. MarketBeat recorded 21 mentions for Sarepta Therapeutics and 12 mentions for CytomX Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.39 beat CytomX Therapeutics' score of 0.34 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sarepta Therapeutics	1 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sarepta Therapeutics beats CytomX Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Editas Medicine has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	7.12	-$160.06M	-$1.23	N/A
Sarepta Therapeutics	$2.20B	0.92	-$713.41M	-$0.96	N/A

Editas Medicine presently has a consensus target price of $5.40, suggesting a potential upside of 83.36%. Sarepta Therapeutics has a consensus target price of $27.71, suggesting a potential upside of 44.80%. Given Editas Medicine's stronger consensus rating and higher probable upside, equities analysts clearly believe Editas Medicine is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Sarepta Therapeutics	6 Sell rating(s)	13 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.11

In the previous week, Sarepta Therapeutics had 10 more articles in the media than Editas Medicine. MarketBeat recorded 21 mentions for Sarepta Therapeutics and 11 mentions for Editas Medicine. Sarepta Therapeutics' average media sentiment score of 0.39 beat Editas Medicine's score of 0.18 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sarepta Therapeutics	1 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

Editas Medicine has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market.

Sarepta Therapeutics has a net margin of -2.94% compared to Editas Medicine's net margin of -281.59%. Sarepta Therapeutics' return on equity of 7.56% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Sarepta Therapeutics	-2.94%	7.56%	2.94%

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 3.1% of Editas Medicine shares are held by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Sarepta Therapeutics beats Editas Medicine on 10 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Sarepta Therapeutics (NASDAQ:SRPT) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Praxis Precision Medicines currently has a consensus target price of $591.83, suggesting a potential upside of 77.43%. Sarepta Therapeutics has a consensus target price of $27.71, suggesting a potential upside of 44.80%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, research analysts clearly believe Praxis Precision Medicines is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.00
Sarepta Therapeutics	6 Sell rating(s)	13 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.11

Praxis Precision Medicines has higher earnings, but lower revenue than Sarepta Therapeutics. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,087.69	-$303.27M	-$13.37	N/A
Sarepta Therapeutics	$2.20B	0.92	-$713.41M	-$0.96	N/A

In the previous week, Praxis Precision Medicines had 16 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 37 mentions for Praxis Precision Medicines and 21 mentions for Sarepta Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.60 beat Sarepta Therapeutics' score of 0.39 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	7 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Sarepta Therapeutics	1 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Praxis Precision Medicines has a beta of 2.76, meaning that its stock price is 176% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Praxis Precision Medicines has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-60.25%	-54.81%
Sarepta Therapeutics	-2.94%	7.56%	2.94%

Summary

Praxis Precision Medicines beats Sarepta Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Vaxcyte?

Sarepta Therapeutics (NASDAQ:SRPT) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 3.1% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Sarepta Therapeutics currently has a consensus target price of $27.71, suggesting a potential upside of 44.80%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 59.83%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	13 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.11
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Vaxcyte has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Vaxcyte	N/A	-32.51%	-29.51%

Sarepta Therapeutics has higher revenue and earnings than Vaxcyte. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.92	-$713.41M	-$0.96	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

In the previous week, Sarepta Therapeutics had 12 more articles in the media than Vaxcyte. MarketBeat recorded 21 mentions for Sarepta Therapeutics and 9 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.65 beat Sarepta Therapeutics' score of 0.39 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	1 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sarepta Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market.

Summary

Sarepta Therapeutics beats Vaxcyte on 8 of the 15 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Cytokinetics?

Sarepta Therapeutics (NASDAQ:SRPT) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

In the previous week, Cytokinetics had 19 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 40 mentions for Cytokinetics and 21 mentions for Sarepta Therapeutics. Cytokinetics' average media sentiment score of 0.62 beat Sarepta Therapeutics' score of 0.39 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	1 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytokinetics	15 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Sarepta Therapeutics has higher revenue and earnings than Cytokinetics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.92	-$713.41M	-$0.96	N/A
Cytokinetics	$88.04M	105.51	-$784.96M	-$6.84	N/A

86.7% of Sarepta Therapeutics shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Sarepta Therapeutics currently has a consensus target price of $27.71, suggesting a potential upside of 44.80%. Cytokinetics has a consensus target price of $98.55, suggesting a potential upside of 32.01%. Given Sarepta Therapeutics' higher possible upside, equities analysts clearly believe Sarepta Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	13 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.11
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.82

Sarepta Therapeutics has a net margin of -2.94% compared to Cytokinetics' net margin of -784.02%. Sarepta Therapeutics' return on equity of 7.56% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Cytokinetics	-784.02%	N/A	-52.86%

Sarepta Therapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Summary

Sarepta Therapeutics beats Cytokinetics on 9 of the 17 factors compared between the two stocks.

Get Sarepta Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRPT vs. The Competition

Export

Metric	Sarepta Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.03B	$3.41B	$6.28B	$12.10B
Dividend Yield	N/A	2.25%	2.78%	5.23%
P/E Ratio	-20.05	15.30	20.55	25.41
Price / Sales	0.92	303.37	545.88	75.53
Price / Cash	N/A	56.93	27.81	36.29
Price / Book	1.76	6.85	9.62	6.65
Net Income	-$713.41M	$24.11M	$3.55B	$333.40M
7 Day Performance	-12.18%	-1.57%	-0.36%	-0.58%
1 Month Performance	-9.66%	3.83%	5.99%	7.66%
1 Year Performance	-47.39%	71.34%	38.59%	35.36%

Sarepta Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRPT Sarepta Therapeutics	3.6325 of 5 stars	$19.14 -1.4%	$27.71 +44.8%	-46.5%	$2.03B	$2.20B	N/A	1,372	Earnings Report
CTMX CytomX Therapeutics	2.5469 of 5 stars	$4.18 flat	$13.44 +221.6%	+315.8%	$711.38M	$76.20M	N/A	170	News Coverage Earnings Report Analyst Upgrade Analyst Revision
EDIT Editas Medicine	3.5395 of 5 stars	$3.00 +3.4%	$5.30 +76.7%	+111.0%	$283.93M	$40.52M	N/A	230	Earnings Report Analyst Downgrade
PRAX Praxis Precision Medicines	3.4756 of 5 stars	$337.61 +4.1%	$590.78 +75.0%	+765.2%	$9.03B	$8.55M	N/A	110	Trending News Earnings Report Analyst Revision
PCVX Vaxcyte	2.6786 of 5 stars	$58.49 +2.7%	$86.00 +47.0%	+73.3%	$8.22B	N/A	N/A	160	Earnings Report Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRPT) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sarepta Therapeutics (SRPT) Competitors

SRPT vs. CTMX, EDIT, PRAX, PCVX, and CYTK

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Summary

How does Sarepta Therapeutics compare to Editas Medicine?

Summary

How does Sarepta Therapeutics compare to Praxis Precision Medicines?

Summary

How does Sarepta Therapeutics compare to Vaxcyte?

Summary

How does Sarepta Therapeutics compare to Cytokinetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT vs. The Competition

Sarepta Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sarepta Therapeutics (SRPT) Competitors

SRPT vs. CTMX, EDIT, PRAX, PCVX, and CYTK

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Do insiders & institutionals believe in CTMX or SRPT?

Is CTMX or SRPT more profitable?

Do analysts recommend CTMX or SRPT?

Which has more risk & volatility, CTMX or SRPT?

Which has higher valuation and earnings, CTMX or SRPT?

Does the media favor CTMX or SRPT?

Summary

How does Sarepta Therapeutics compare to Editas Medicine?

Which has higher earnings & valuation, EDIT or SRPT?

Do analysts prefer EDIT or SRPT?

Does the media prefer EDIT or SRPT?

Which has more volatility and risk, EDIT or SRPT?

Is EDIT or SRPT more profitable?

Do institutionals and insiders hold more shares of EDIT or SRPT?

Summary

How does Sarepta Therapeutics compare to Praxis Precision Medicines?

Do analysts recommend PRAX or SRPT?

Which has better earnings and valuation, PRAX or SRPT?

Does the media refer more to PRAX or SRPT?

Do insiders & institutionals have more ownership in PRAX or SRPT?

Which has more volatility and risk, PRAX or SRPT?

Is PRAX or SRPT more profitable?

Summary

How does Sarepta Therapeutics compare to Vaxcyte?

Do institutionals and insiders have more ownership in SRPT or PCVX?

Do analysts recommend SRPT or PCVX?

Is SRPT or PCVX more profitable?

Which has stronger valuation and earnings, SRPT or PCVX?

Does the media favor SRPT or PCVX?

Which has more volatility & risk, SRPT or PCVX?

Summary

How does Sarepta Therapeutics compare to Cytokinetics?

Does the media favor SRPT or CYTK?

Which has higher earnings & valuation, SRPT or CYTK?

Do institutionals and insiders hold more shares of SRPT or CYTK?

Do analysts prefer SRPT or CYTK?

Is SRPT or CYTK more profitable?

Which has more risk & volatility, SRPT or CYTK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT vs. The Competition

Sarepta Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools